CSL Stock

CSL Current Assets

The Current Assets of CSL (CSL.AX) as of Sep 10, 2026 is 11.85 B USD. In the previous year, Current Assets was 10.77 B USD — a change of 10.05% (higher).

Current Assets

11.85 BUSD

YoY

10.05%

Last updated:

Current Assets of CSL is 2026 11.85 B USD. Current Assets of CSL was 2025 10.77 B USD. It decreases by 10.05% higher compared to the previous year.

The CSL Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
4.99 B USD
Jan 1, 2019
5.54 B USD
Jan 1, 2020
6.45 B USD
Jan 1, 2021
7.39 B USD
Jan 1, 2022
16.46 B USD
Jan 1, 2023
9.26 B USD
Jan 1, 2024
10.77 B USD
Jan 1, 2025
11.85 B USD
The CSL Current Assets history
YEARCurrent AssetsYoY
11.85 BUSD+10.05%
10.77 BUSD+16.30%
9.26 BUSD-43.75%
16.46 BUSD+122.75%
7.39 BUSD+14.64%
6.45 BUSD+16.36%
5.54 BUSD+10.94%
4.99 BUSD+8.51%
4.60 BUSD+20.54%
3.82 BUSD+14.34%
3.34 BUSD+4.09%
3.21 BUSD-1.60%
3.26 BUSD-6.21%
3.48 BUSD+17.47%
2.96 BUSD+5.53%
2.80 BUSD-29.78%
3.99 BUSD+59.66%
2.50 BUSD+32.40%
1.89 BUSD+9.06%
1.73 BUSD+1.88%
1.70 BUSD+19.89%
1.42 BUSD+181.35%
504.00 MUSD+21.15%
416.00 MUSD+42.96%
291.00 MUSD-19.83%
363.00 MUSD+179.23%
130.00 MUSD+18.18%
110.00 MUSD-6.78%
118.00 MUSD
Access this data via the Eulerpool API

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Current Assets of CSL is 11.85 B USD in 2026.

Current Assets of CSL changed from 10.77 B USD to 11.85 B USD, representing a 10.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets CSL since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's CSL historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — CSL

All Key Metrics — CSL